ATX-304 (formerly O304) vs SANA (MVD1)
updated
ATX-304 (formerly O304) (tier B) vs SANA (MVD1) (tier B): what each is, half-life and source counts side by side.
ATX-304 (formerly O304) · tier B
an investigational oral AMPK activator with one small randomized diabetes trial, a newer obesity pilot, and an animal pharmacokinetic curve that cannot establish a human dosing interval.
tier rationale
B reflects a 65-person, 28-day diabetes trial and a 23-person, eight-week obesity and prediabetes study with measurable metabolic effects. Neither study established weight-loss efficacy or safety at weight-loss doses.
SANA (MVD1) · tier B
an investigational nitroalkene small molecule that targets creatine-kinase-dependent thermogenesis, with mouse fat-loss data, a small exploratory 15-day human weight signal, and a high-dose renal safety signal in phase 1.
tier rationale
B-tier reflects direct human PK and safety data, a small exploratory 15-day human weight signal, and a substantial mechanistic and animal-efficacy paper. It does not rise to A because the 41-person program was phase 1 rather than a confirmatory efficacy trial, and two of three participants at the highest single dose developed renal tubular injury. Long-term efficacy and safety remain unresolved.
at a glance
| ATX-304 (formerly O304) | SANA (MVD1) | |
|---|---|---|
| tier | B | B |
| category | weight loss | weight loss |
| sources | 6 | 1 |
| claims evaluated | 4 | 4 |
| half-life | human terminal half-life not published; approximately 11 hours shown only as a low-confidence mouse apparent-decline proxy | approximately 1.6 to 2.0 hours in the first-in-human oral phase 1 study |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.